Breaking Free from Rhinitis: A Complete Guide to Desensitization Therapy

Introduction

Allergic rhinitis, seemingly a minor ailment, can cause countless patients to suffer from sneezing fits and runny noses and eyes during pollen seasons or in dust mite environments, severely impacting sleep, work, and study. According to World Health Organization data, approximately 10%-30% of adults worldwide are affected. Traditional antihistamines and nasal corticosteroids can quickly relieve symptoms but require long-term use and cannot alter the allergic constitution. Desensitization therapy, or allergen immunotherapy, is currently the only method that may address the underlying cause. By gradually increasing the dose of allergen extracts, it allows the immune system to gradually "adapt" to allergens, thereby reducing or even eliminating allergic symptoms. This article provides a comprehensive analysis of desensitization therapy from the perspectives of principles, process, and suitable candidates, helping you address allergic rhinitis scientifically.

Principles of Desensitization Therapy: Making the Immune System "Accustomed"

The core concept of desensitization therapy is "fighting fire with fire." Simply put, it involves repeated, regular exposure to small doses of allergens (e.g., dust mites, pollen) to gradually induce immune tolerance. Specific mechanisms include regulating T cell subset balance, suppressing Th2-type immune responses, promoting IgG4 antibody production, and blocking IgE-mediated allergic cascades. Studies show that after approximately 3 years of desensitization therapy, allergen-specific IgE levels in patients significantly decrease, while IgG4 levels rise, with nasal and ocular symptom scores improving by 50%-70%, and the effects can last for several years.

Two Conventional Methods: Sublingual vs. Subcutaneous Injection

Currently, mainstream desensitization therapy is divided into two types:

Subcutaneous Immunotherapy (SCIT): The traditional method, requiring weekly or monthly hospital injections, divided into a dose escalation phase and a maintenance phase. It takes effect relatively quickly but requires frequent visits and carries a slight risk of systemic reactions.

Sublingual Immunotherapy (SLIT): A newer method, where allergen drops or tablets are placed under the tongue for 1-2 minutes before swallowing, taken once daily, and can be done at home. It has a better safety profile and is especially suitable for children and those who fear injections.

Both have comparable efficacy, but SLIT has gradually become mainstream in Europe due to its convenience and safety. In China, multiple standardized allergen preparations have been approved, such as dust mite drops (Changdi) and pollen tablets. The choice of method depends on patient preference, allergen type, and physician recommendations.

Treatment Process: From Assessment to Long-Term Management

Desensitization therapy is not a quick fix and typically requires 2-3 years. The standard process includes:

Precise Diagnosis: Identify the allergen type and concentration through skin prick tests or serum-specific IgE testing.

Treatment Plan Development: The physician develops an individualized plan based on allergens, age, symptom severity, and comorbid conditions (e.g., asthma).

Dose Escalation Phase: Lasting about 4-6 months, starting from a very low dose and gradually increasing to the maintenance dose, with close monitoring of reactions.

Maintenance Phase: Maintain a fixed dose, with subcutaneous injections every 4-6 weeks or sublingual administration once daily, continuing for at least 18-24 months.

Efficacy Evaluation: Assess symptom scores and medication use every 6 months; effects typically appear after 6 months, with significant improvement after 1 year.

Throughout the process, patients need to keep symptom diaries, attend regular follow-ups, and implement environmental controls (e.g., anti-mite measures).

Who Is Suitable for Desensitization Therapy?

Desensitization therapy is not for everyone; the following individuals benefit most:

Symptoms persisting for more than 2 years with poor medication control;

Concurrent mild asthma or allergic conjunctivitis;

Clear allergen identification (e.g., dust mites, pollen) that is difficult to fully avoid;

Age 5 and above (children require physician evaluation);

Those unwilling to rely on long-term medication.

However, caution is needed in the following cases: severe uncontrolled asthma, autoimmune diseases, malignancies, or current use of beta-blockers. Pregnant women may continue maintenance therapy but should not start new courses.

Side Effects and Risks: Are They Manageable?

The overall safety profile of desensitization therapy is good, but local and systemic reactions can occur. Local reactions commonly include redness, swelling, and itching at the injection site, or a tingling sensation under the tongue, which usually resolve on their own. Systemic reactions are rare (incidence ~1%), including urticaria, worsening rhinitis, and very rarely anaphylactic shock, but most occur during the dose escalation phase. Therefore, subcutaneous injections must be administered in a medical facility with a 30-minute observation period; the first sublingual dose should also be taken under medical supervision. Overall, the incidence of severe adverse reactions is below 0.1%, and they can be effectively prevented with standardized procedures.

Recommendations for International Patients

If you are considering desensitization therapy, the following suggestions may be helpful:

Confirm Diagnosis: Complete allergen testing at a reputable hospital; do not purchase desensitization medications on your own.

Weigh Pros and Cons: Fully discuss with your physician the treatment duration, costs, and potential inconveniences.

Choose Timing: If you plan to return home or travel long-term, consider treatment continuity, as interruptions may affect efficacy.

Combine with Environmental Control: During treatment, continue environmental management (e.g., using anti-mite bedding, air purifiers) to enhance effectiveness.

Consider Costs and Insurance: In China, the cost of desensitization therapy varies by preparation and duration; sublingual administration costs approximately 5,000-10,000 RMB per year, and subcutaneous injection approximately 8,000-15,000 RMB per year, with partial reimbursement possible through medical insurance in some cities.

Mei Jia Kang offers international patients one-stop services for allergic rhinitis specialist diagnosis and desensitization therapy, including allergen testing, treatment plan customization, and long-term follow-up. You can learn more through Medical Services or get preliminary cost estimates via Cost Estimator. If you have questions, feel free to Contact Us to schedule an expert consultation.

Desensitization therapy is a "patience project," but it may bring long-term benefits, freeing you from rhinitis and restoring free breathing.